Factors Related to Adverse Events in Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coordinated multi-center project with several complementary goals in each one of the sub-projects included. Objectives: 1.To determine risk factors of death, or major complications in the short term; 2.To determine risk factors of death, tumor recurrence, major complications, readmission or deterioration of quality of life in the mid term; 3.Evaluation of patient reported outcomes from before the intervention to the end of the follow-up. 4.To study the role of immunohisto-chemistry markers in the prediction of similar adverse results. This sub-project (coordinator) will approach the determination of risk factors of death, tumor recurrence, major complications, readmission and deterioration of quality of medium term life (1-2 years). Methodology. Design: prospective cohort study with 2 years follow-up after the surgical intervention. Participant centers: 18 hospitals of 6 Autonomous Communities of all Spain. Patients diagnosed of colorectal cancer surgically intervened. Variables: pre-intervention, those of the hospital admission, sociodemographic, immunohisto-chemistry and clinical parameters, that could be in relation to the outcomes to study. Statistic analysis: a derivation sample will be created where the possible predicting parameters will be identified, by cancer of colon or rectum. Predictive models will be created with a good discriminative capacity. A validation of those models will be performed in a validation sub-sample. Logistic and Cox regression models will be used. Simulation models for the prediction of discreet events in the long term will be used.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Organ/Space Surgical Site Infection and Recurrence and Survival in Rectal Cancer Surgery

NCT06382415

Rectal Cancer Organ-Space Surgical Site Infection

COMPLETED

Factors Affecting the Results of Treatment of Patients With Colorectal Cancer

NCT06050447

Colorectal Cancer Colon Cancer Rectal Cancer +3 more

RECRUITING

Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin) in Patients With Mid-low Rectal Cancer

NCT03107650

Rectal Cancer

COMPLETED

Bowel Dysfunction After Rectal Cancer Treatment

NCT05020132

Low Anterior Resection Syndrome

COMPLETED

Prospective Randomised Study Comparing Laparoscopic Versus Open Surgery in Patients With Rectal Cancer

NCT00782457

RECTAL CANCER

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective cohort study included patients drawn from 22 hospitals belonging to the Spanish National Health Service (SNS), which covers the majority (99.8%) of the population of Spain. All covered residents have free access to their primary care physician and to the emergency departments of the hospitals. All of the hospitals have similar technological and human resources.

Patients with a diagnosis of colon cancer attending the surgical services of any of these hospitals to undergo surgery between June 2010 and December 2012 were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, a patient had to provide informed consent. All information was kept confidential. The Institutional Review Boards of the participating hospitals approved this project.

Data collected Data collected upon hospital admission included information on sociodemographic data, clinical data (including information about onset of symptoms, habits, personal and family background, comorbidities, diagnostic tests, pre-intervention treatments), preoperative data (including analytical, tumor markers and diagnostic tests), data of the outpatient anesthesia data on the surgical intervention, pathology data, and data related to the remaining days of admission (including the presence of complications, need for reintervention or death). Subsequently, data were collected up to 30 days after surgery (analytical, diagnostic tests, presence of complications, readmissions, reintervention or death). Finally, information was collected through the year including need for radiation therapy, chemotherapy (treatment schedule, cycles, complications of treatment, supportive care), laboratory results and diagnostic tests performed, presence of complications, tumor recurrence, readmission or reintervention and death.

Patients completed the following questionnaires before surgery and one year after surgery: EuroQol-5D, EORTC QLQ-C30 (The European Organization for Research and Treatment of Cancer quality of life questionnaire) and QLQ-CR29 (European Organisation for Research and Treatment of Cancer questionnaire module for colorectal cancer), and HADS. The EuroQol-5D is a generic HRQoL questionnaire which has demonstrated good psychometric properties and allow for comparison with other populations. It has been translated and validated in Spanish. This instrument consists of two parts: the first is a description of the state of health in five dimensions: mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Each of these dimensions is measured by three answer options that define different levels of severity. The second is a visual analogue scale in which patients rate their health on a scale displayed in the form of a thermometer (20 mm), whose ends are 0 (worst imaginable health state) to 100 (best state imaginable health). The EORTC QLQ-C30 is a questionnaire for evaluating the HRQoL for cancer patients undergoing treatment, which has shown good validity and reliability in its Spanish adaptation (Cronbach's alpha coefficient of 0.7). It is one of the instruments measuring quality of life in cancer patients most commonly used and allow the comparison of the results obtained in patients with colorectal cancer patients with other cancers. It consists of 30 items, 28 of them with four possible answers (in all, a little, a lot, a lot) and two items with seven Alternative (visual analogue scale where one is "very poor" and seven "excellent"). The timeframe should refer to the previous week. The scores on each scale are transformed so that the final values are between 0 and 100. In addition to this overall score, the instrument consists of three scales: Global health status: in which a high score represents a high performance in terms of overall health; Functional -scale: consists of five subscales of operation: physical, role, emotional, cognitive and social; Symptoms scale consisting of a number of symptoms: fatigue, nausea, vomiting, pain, dyspnea, insomnia, decreased appetite, constipation, diarrhea and financial difficulties. A high score on each of these symptoms represents a high level of symptoms or problems in this area. The QLQ-CR29 was then developed after revising the QLQ-CR38, and was demonstrated internationally to have both sufficient validity and reliability to support its use as a supplement to the EORTC QLQ-C30 to assess patient-reported outcomes during treatment for colorectal cancer in clinical trials and other settings. The QLQ-CR29 contains 29 items, and is described in detail elsewhere. Briefly, there are 18 items addressing gastrointestinal symptoms, pain and problems with micturition, and there are separate scales for the participants with or without a stoma and separate items addressing sexual function for men and women. The response categories for each item are the same as those used in the QLQ-C30.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with colorectal cancer

One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.

No intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:

* Patients were eligible for the study if they were included in the surgical waiting list of one of the participating hospitals with a diagnosis of surgically resectable colon or rectum cancer. Colon or rectum cancer diagnosis was based on anatomopathological diagnosis after a biopsy by colonoscopy. Inclusion criteria were having diagnosed with colon cancer (up to 15 cm above the anal margin) and rectum (between the anal margin and 15 cm above it), where curative and / or palliative surgery for treatment by first time were applied and who sign the informed consent to participate in the study consent.

Exclusion Criteria:

* Exclusion criteria were colon or rectum in situ cancer, unresectable tumor, severe mental or physical conditions which preclude the patient to respond to questionnaires, terminal patients, patients unable to respond to questionnaires from any cause or who do not give their consent to participate in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

JOSE M QUINTANA-LOPEZ, MD PhD

PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jose M Quintana, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Galdakao-Usansolo

References

Explore related publications, articles, or registry entries linked to this study.

Orive M, Barrio I, Lazaro S, Gonzalez N, Bare M, de Larrea NF, Redondo M, Cortajarena S, Bilbao A, Aguirre U, Sarasqueta C, Quintana JM; REDISSEC-CARESS/CCR group. Five-year follow-up mortality prognostic index for colorectal patients. Int J Colorectal Dis. 2023 Mar 9;38(1):64. doi: 10.1007/s00384-023-04358-0.

Reference Type DERIVED

PMID: 36892600 (View on PubMed)

Orive M, Anton-Ladislao A, Lazaro S, Gonzalez N, Bare M, Fernandez de Larrea N, Redondo M, Bilbao A, Sarasqueta C, Aguirre U, Quintana JM; REDISSEC-CARESS/CCR group. Anxiety, depression, health-related quality of life, and mortality among colorectal patients: 5-year follow-up. Support Care Cancer. 2022 Oct;30(10):7943-7954. doi: 10.1007/s00520-022-07177-1. Epub 2022 Jun 23.

Reference Type DERIVED

PMID: 35737143 (View on PubMed)

Quintana JM, Anton-Ladislao A, Lazaro S, Gonzalez N, Bare M, de Larrea NF, Redondo M, Escobar A, Sarasqueta C, Garcia-Gutierrez S, Aguirre U, Briones E, Group FTRCR. Quality Indicators and Outcomes in a Prospective Cohort of Colorectal Cancer Patients. J Gastrointest Cancer. 2023 Mar;54(1):20-26. doi: 10.1007/s12029-021-00779-8. Epub 2021 Dec 10.

Reference Type DERIVED

PMID: 34893952 (View on PubMed)

Gonzalez N, Lorono A, Aguirre U, Lazaro S, Bare M, Redondo M, Briones E, Sarasqueta C, Bilbao A, de Larrea NF, Quintana JM; REDISSEC-CARESS/CCR group. Risk scores to predict mortality 2 and 5 years after surgery for colorectal cancer in elderly patients. World J Surg Oncol. 2021 Aug 26;19(1):252. doi: 10.1186/s12957-021-02356-6.

Reference Type DERIVED

PMID: 34446044 (View on PubMed)

Quintana JM, Anton-Ladislao A, Lazaro S, Gonzalez N, Bare M, de Larrea NF, Redondo M, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S; REDISSEC CARESS-CCR (Results and Health Services Research in Colorectal Cancer)- group. Predictors of readmission and reoperation in patients with colorectal cancer. Support Care Cancer. 2020 May;28(5):2339-2350. doi: 10.1007/s00520-019-05050-2. Epub 2019 Sep 4.

Reference Type DERIVED

PMID: 31485982 (View on PubMed)

Mar J, Anton-Ladislao A, Ibarrondo O, Arrospide A, Lazaro-Aramburu S, Gonzalez N, Bare M, Escobar A, Redondo M, Quintana JM; REDISSEC-CARESS/CCR group. Stage- and age-adjusted cost-effectiveness analysis of laparoscopic surgery in rectal cancer. Surg Endosc. 2020 Mar;34(3):1167-1176. doi: 10.1007/s00464-019-06867-y. Epub 2019 May 28.

Reference Type DERIVED

PMID: 31140003 (View on PubMed)

Orive M, Aguirre U, Gonzalez N, Lazaro S, Redondo M, Bare M, Anula R, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S, Quintana JM; REDISSEC-CARESS/CCR group. Risk factors affecting hospital stay among patients undergoing colon cancer surgery: a prospective cohort study. Support Care Cancer. 2019 Nov;27(11):4133-4144. doi: 10.1007/s00520-019-04683-7. Epub 2019 Feb 22.

Reference Type DERIVED

PMID: 30793242 (View on PubMed)

Quintana JM, Anton-Ladisla A, Gonzalez N, Lazaro S, Bare M, Fernandez de Larrea N, Redondo M, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S; REDISSEC-CARESS/CCR group. Outcomes of open versus laparoscopic surgery in patients with colon cancer. Eur J Surg Oncol. 2018 Sep;44(9):1344-1353. doi: 10.1016/j.ejso.2018.05.030. Epub 2018 Jun 6.

Reference Type DERIVED

PMID: 29921557 (View on PubMed)

Mar J, Anton-Ladislao A, Ibarrondo O, Arrospide A, Lazaro S, Gonzalez N, Bare M, Callejo D, Redondo M, Quintana JM; REDISSEC-CARESS/CCR group. Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer. Surg Endosc. 2018 Dec;32(12):4912-4922. doi: 10.1007/s00464-018-6250-9. Epub 2018 Jun 4.

Reference Type DERIVED

PMID: 29869084 (View on PubMed)

Arostegui I, Gonzalez N, Fernandez-de-Larrea N, Lazaro-Aramburu S, Bare M, Redondo M, Sarasqueta C, Garcia-Gutierrez S, Quintana JM; REDISSEC CARESS-CCR Group. Combining statistical techniques to predict postsurgical risk of 1-year mortality for patients with colon cancer. Clin Epidemiol. 2018 Mar 6;10:235-251. doi: 10.2147/CLEP.S146729. eCollection 2018.

Reference Type DERIVED

PMID: 29563837 (View on PubMed)

Bare M, Alcantara MJ, Gil MJ, Collera P, Pont M, Escobar A, Sarasqueta C, Redondo M, Briones E, Dujovne P, Quintana JM; CARESS-CCR Study Group. Validity of the CR-POSSUM model in surgery for colorectal cancer in Spain (CCR-CARESS study) and comparison with other models to predict operative mortality. BMC Health Serv Res. 2018 Jan 29;18(1):49. doi: 10.1186/s12913-018-2839-x.

Reference Type DERIVED

PMID: 29378647 (View on PubMed)

Quintana JM, Gonzalez N, Anton-Ladislao A, Redondo M, Bare M, Fernandez de Larrea N, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S, Aguirre U; REDISSEC-CARESS/CCR group. Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project. BMC Cancer. 2016 Jul 8;16:435. doi: 10.1186/s12885-016-2475-y.

Reference Type DERIVED

PMID: 27391216 (View on PubMed)